The clinical spectrum encompasses multiple subtypes, including classic dermatomyositis, cancer-associated dermatomyositis, clinically amyopathic dermatomyositis (CADM), and the increasingly recognized anti-melanoma differentiation-associated gene 5 (anti-MDA5) dermatomyositis [2]. Here, IFIH1 is linked to dermatomyositis.